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Of 1,000 births worldwide, in one embryo the
neural tube will fail to close properly 28 days
after conception, resulting in some form of
neural tube defect (NTD). Failed closure at
the cranial end, known as anencephaly, is a
lethal condition, whereas failed closure at the
caudal end usually results in a myelomeningo-
cele. NTDs are the most common debilitating
birth defect. Familial studies indicate a signiﬁ-
cant genetic component to NTDs, with a
40-fold increase in risk in ﬁrst-degree relatives
(Elwood et al. 1992). Myriad environmental
exposures have been implicated in the devel-
opment of NTDs; most notably, a signiﬁcant
decrease in risk can be achieved by maternal
folic acid supplementation before conception.
The mechanism by which dietary folate
supplementation prevents NTDs is poorly
understood (MRC Vitamin Study Research
Group 1991). Folic acid derivatives are essen-
tial for the synthesis of DNA, cell division, tis-
sue growth, and DNA methylation (Morrison
et al. 1998). Methylation enables proper gene
expression and chromosome structure mainte-
nance, both of which are critical in the devel-
oping embryo (Razin and Kantor 2005). The
folate and methionine cycles are linked by the
conversion of homocysteine to methionine
(Figure 1). In the absence of food frequency
data, maternal vitamin supplementation can
also serve as a proxy for overall health because
of the positive correlation between supplement
intake, diet, and a healthy lifestyle (Slesinski
et al. 1996). Vitamin supplementation is an
important cofactor to consider when studying
nutritionally related genes.
Animal models demonstrate that pericon-
ceptional folate supplementation protects
against congenital defects in the face, neural
tube, and conotruncal region of the heart. Low
folate could directly limit its availability to cells
or indirectly disrupt methionine metabolism,
thereby increasing homocysteine in the mater-
nal serum (Rosenquist and Finnell 2001).
Either mechanism implicates folate receptor and
methionine–homocysteine regulatory genes.
Folate enters cells by folate receptor 1
[FOLR1; GenBank accession no. NM_016725
(http://www.ncbi.nih.gov/GenBank)] and
folate receptor 2 (FOLR2; GenBank accession
no. NM_000803) or carrier-mediated internal-
ization by solute carrier family 19 member 1
(SLC19A1; GenBank accession no. U15939),
also known as reduced folate carrier protein 1.
Transcobalamin II (TCN2; GenBank acces-
sion no. NM_000355) imports vitamin B12,
cobalamin, a cofactor for another folate
enzyme, 5-methyltetrahydrofolate-homocys-
teine methyltransferase (MTR; GenBank
accession no. NM_000254).The reactions
within the folate metabolism cycle can be very
complex, with methylenetetrahydrofolate
dehydrogenase 1 (MTHFD1; GenBank acces-
sion no. J04031), serine hydroxymethyl-
tranferase 1 (SHMT1; GenBank accession no.
NM_004169), and 5,10-methylenetetrahy-
drofolate reductase (MTHFR; GenBank
accession no. NM_005957) being widely
studied in the NTD literature.
MTHFR rs1801133 is the most frequently
investigated polymorphism in NTDs with
conflicting results in different populations:
Dutch and Irish populations associate the TT
allele with risk (Shields et al. 1999; van der Put
et al. 1995), whereas a protective effect is seen
in Italians (De Marco et al. 2002) and other
populations have no evidence of association
(Gonzalez-Herrera et al. 2002; Revilla et al.
2003; Stegmann et al. 1999). This polymor-
phism also has a conﬁrmed role heart disease
(Frosst et al. 1995).
Homocysteine can accumulate from low
dietary folate, cobalamin, and/or genetic factors
(Morrison et al. 1998; Ramsbottom et al.
1997) and is elevated in some NTD mothers
(Mills et al. 1995; Steegers-Theunissen et al.
1994). Homocysteine itself may be teratogenic
(Rosenquist et al. 1996) or impair substrates for
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BACKGROUND: Folate metabolism pathway genes have been examined for association with neural
tube defects (NTDs) because folic acid supplementation reduces the risk of this debilitating birth
defect. Most studies addressed these genes individually, often with different populations providing
conﬂicting results.
OBJECTIVES: Our study evaluates several folate pathway genes for association with human NTDs,
incorporating an environmental cofactor: maternal folate supplementation.
METHODS: In 304 Caucasian American NTD families with myelomeningocele or anencephaly, we
examined 28 polymorphisms in 11 genes: folate receptor 1, folate receptor 2, solute carrier family 19
member 1, transcobalamin II, methylenetetrahydrofolate dehydrogenase 1, serine hydroxymethyl-
transferase 1, 5,10-methylenetetrahydrofolate reductase (MTHFR), 5-methyltetrahydrofolate-homo-
cysteine methyltransferase, 5-methyltetrahydrofolate-homocysteine methyltransferase reductase,
betaine-homocysteine methyltransferase (BHMT), and cystathionine-beta-synthase.
RESULTS: Only single nucleotide polymorphisms (SNPs) in BHMT were signiﬁcantly associated in
the overall data set; this signiﬁcance was strongest when mothers took folate-containing nutritional
supplements before conception. The BHMT SNP rs3733890 was more signiﬁcant when the data
were stratiﬁed by preferential transmission of the MTHFR rs1801133 thermolabile T allele from
parent to offspring. Other SNPs in folate pathway genes were marginally signiﬁcant in some analy-
ses when stratiﬁed by maternal supplementation, MTHFR, or BHMT allele transmission.
CONCLUSIONS: BHMT rs3733890 is significantly associated in our data set, whereas MTHFR
rs1801133 is not a major risk factor. Further investigation of folate and methionine cycle genes will
require extensive SNP genotyping and/or resequencing to identify novel variants, inclusion of envi-
ronmental factors, and investigation of gene–gene interactions in large data sets. 
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[Online 15 June 2006]methylation reactions (Essien and Wannberg
1993). Enzymes that degrade homocysteine
regulate homocysteine levels; for example,
MTR converts homocysteine to methionine
and folate to tetrahydrofolate (Trembath et al.
1999). 5-Methyltetrahydrofolate-homocysteine
methyltransferase reductase (MTRR; GenBank
accession no. AF025794) maintains MTR in its
active state. Betaine-homocysteine methyltrans-
ferase  (BHMT; GenBank accession no.
BC012616) remethylates homocysteine to
methionine with a betaine cofactor (Morin
et al. 2003). Cystathionine-beta-synthase (CBS;
GenBank accession no. NM_000071) controls
homocysteine levels by degrading homocysteine
into cystathionine (Morrison et al. 1998).
Detecting moderate effects of multiple folate
genes will be particularly difficult if they are
interactive or additive with environmental
impacts (Morrison et al. 1998). This complex
pathway has several known metabolic inter-
actions, such as MTRR maintaining MTR in an
active state. Previous studies found an associa-
tion of MTHFR and MTRR (Gueant-Rodriguez
et al. 2003; Wilson et al. 1999) plus CBS and
the MTHFR thermolabile variant with NTDs
(Afman et al. 2003; Ramsbottom et al. 1997;
Speer et al. 1999).
Thus, genes involved in folate metabolism
are compelling candidates for NTDs, from both
a genetic and an environmental perspective.
Material and Methods
Sample population. All polymorphisms were
genotyped in 304 families with at least one
individual affected with an NTD and their
first-degree relatives when available. These
families represent 240 complete trios and
64 families with only one parent, whereas 16 of
these families had two or more affected individ-
uals. Cases with lumbosacral myelomeningocele
were classiﬁed as affected in the narrow diag-
nostic criteria, and any level NTD was affected
in the broad criteria. These Caucasian families
were collected from 13 sites across the United
States through myelodysplasia clinics, neuro-
surgical referrals, our study website, and word
of mouth. The family-based study design is
robust to potential population stratification
and particularly useful when sampling over
such a wide geographic area. Most affected
individuals were ascertained as children (aver-
age age at sample, 14.3 years) with no sex dif-
ferences. In 74% of NTD case mothers,
extensive environmental exposure interviews
were conducted, including pre- and post-
conceptional vitamin use. Table 1 outlines the
sample sizes subdivided by diagnostic criteria
and maternal folate supplementation. This
study was approved by the Duke University
Medical Center Institutional Review Board,
and all data and samples were collected after
informed consent of subjects.
SNP genotyping. Eleven genes of the folate
pathway are included in our study and were
selected from previously published NTD
research (Table 2). Three genes that degrade
homocysteine (MTR, BHMT, and CBS) were
more thoroughly genotyped based on
HapMap Release 19 (International HapMap
Project 2005) tagging single nucleotide poly-
morphisms (SNPs) and location in the gene
(Figure 2). All but two genetic variants were
genotyped by commercially available TaqMan
allelic discrimination assays (Assay-on-Demand
and Assay-by-Design, Applied Biosystems,
Foster City, CA). Previously published poly-
merase chain reaction (PCR) primers for a
68-bp insertion in CBS exon 8 (Morrison et al.
1998) produced results that did not pass the
quality control measures outlined below.
Sequencing of the insertion showed a tandem
duplication such that the forward primer
hybridized before and within the insertion. We
used a forward primer 58 bp further upstream
of the insertion producing 242 or 310 bases
fragments (forward, 5´-CGGCGGTATTG-
GCCACTC-3´; reverse, 5´ GGCCGGGC-
TCTGGACTC-3´). The SLC19A1 SNP
rs1051266 was genotyped by melting curve
analysis in the MGB Eclipse Probe System
(Belousov et al. 2004). All PCR ampliﬁcation
used the GeneAmp PCR system 9700 thermo-
cyclers (Applied Biosystems) according to assay
speciﬁcations. Fluorescence was detected with
the ABI Prism 7900HT Sequence Detection
System and analyzed with ABI Prism Sequence
Detection System software (version 2.0;
Applied Biosystems). Quality control measures
consisted of two reference samples from the
Centre d’Etude du Polymorphisme Humain in
Paris, France, and 24 duplicated samples per
384-well plate plus blinded from laboratory
technicians. These 26 samples had to match
completely, and at least 90% of all samples had
to be successfully genotyped for the polymor-
phism to pass quality control. Genotypes were
also checked for Mendelian inconsistencies
within families.
Statistical analysis. Family-based associa-
tion analysis was performed using the pedigree
disequilibrium test (PDT) (Martin et al. 2000)
and association in the presence of linkage
(APL) test (Martin et al. 2003). Because of the
mixed family types and incomplete sampling
in our data set, PDT will take advantage of
multiplex families, whereas APL performs
better with missing data. These tests were
Boyles et al.
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Table 1. Sample set details for the narrow (lumbo-
sacral myelomeningocele only) and broad (any
level NTD) diagnostic groups divided by maternal
vitamin supplementation that was available for
approximately 75% of mothers of affecteds.
Data set Narrow Broad
Full data set
Families 279 304
Affecteds 297 332
Samples 1,158 1,259
Folate before conception
Families 69 76
Affecteds 75 85
Samples 307 330
No folate before conception
Families 141 149
Affecteds 151 165
Samples 617 653
Figure 1. The folate and methionine cycles highlighting the 11 genes included in this study. Substrates are
shown in rectangular boxes; enzymes are shown in ellipses. Adapted from Nijhout et al. (2004) and Reed
et al. (2004). Substrate abbreviations: AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine;
DHF, dihydrofolate; 5,10-CH-THF, 5,10-methenyltetrahydrofolate; 5,10-CH2-THF, 5,10-methylenetetrahydrofo-
late; THF, tetrahydrofolate; 5mTHF,  5-methyltetrahydrofolate; 10f-THF, 10-formyltetrahydrofolate. Enzyme
abbreviations not included elsewhere: AICART, aminoimidazolecarboxamide ribotide transformylase; DHFR,
dihydrofolate reductase; FTD, 10-formyltetrahydrofolate dehydrogenase; FTS, 10-formyltetrahydrofolate
synthase; GNMT, glycine N-methyltransferase; MAT, methionine adenosyltransferase; meth,
S-adenosylmethionine-dependent methyltransferases; MTCH, 5,10-methylenetetrahydrofolate cyclohydro-
lase; NE, nonenzymatic interconversion of THF and 5,10-CH2-THF; PGT, phosphoribosyl glycinamidetrans-
formylase; SAHH, S-adenosylhomocysteine hydrolase; TS, thymidylate synthase. 
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SAHHperformed on all SNPs for the narrow and
broad phenotypes in the overall data set as well
as those subdivided by maternal folate supple-
mentation, BHMT allele transmission, and
MTHFR allele transmission. All SNPs were
checked for Hardy-Weinberg equilibrium
(HWE) separately in unrelated affected indi-
viduals and unaffected relatives in the com-
plete data set using genetic data analysis
(Weir 1996). The reported p-values have not
been corrected for multiple testing, but a
strict correction is not critical given the bio-
logical plausibility implicating these genes
in NTDs. Linkage disequilibrium (LD)
between the SNPs in the same gene was cal-
culated using the Graphical Overview of
Linkage Disequilibrium (GOLD) software
package (Abecasis and Cookson 2000).
Results
Single gene associations with an environmental
stratiﬁcation. The initial analysis of the entire
data set for 28 SNPs in 11 genes (Table 3)
found associations: BHMT rs3733890 (narrow
PDT p = 0.023, narrow APL p = 0.058, broad
PDT p = 0.025, broad APL p = 0.035) and
BHMT rs558133 (broad PDT p = 0.025,
broad APL p = 0.061). All SNPs were in HWE
except the MTHFD1 SNP rs2236225 in
affected individuals only (data not shown).
When subdivided by case mothers’ dietary
supplementation with folate 3 months before
conception, the BHMT associations were sig-
nificant only in the supplemented group:
rs3733890 (narrow PDT p = 0.027, narrow
APL p = 0.055, broad PDT p = 0.016, broad
APL p = 0.027) and rs558133 (narrow PDT
p = 0.036, broad PDT p = 0.012).
When all SNPs were analyzed in the strati-
ﬁed data set, two other genes had signiﬁcant
associations (Table 3). MTHFR rs1801133
was associated by APL with the narrow pheno-
type in families that did not supplement (p =
0.046). Also in the nonsupplementing families,
CBS was associated by PDT with the broad
phenotype in rs234715 (p = 0.015) and
rs4920037 (p = 0.037) and SNPs in MTR
showed signiﬁcance: rs1092535 (narrow PDT
p = 0.066, narrow APL p = 0.031, broad
PDT p = 0.040, broad APL p = 0.04) and
rs4659743 (narrow APL p = 0.013, broad
PDT p = 0.041, broad APL p = 0.010).
Folate genes associated with NTDs
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Table 2. SNPs genotyped in the data set.
Gene symbol Gene name GenBank accession no. rs no. Type of SNP
FOLR1 folate receptor 1 NM_016725 rs2071010 Intronic
FOLR2 folate receptor 2 NM_000803 rs2298444 Intronic
SLC19A1 solute carrier family 19 member 1 U15939 rs1051266 Nonsynonymous
TCN2 transcobalamin II NM_000355 rs1801198 Nonsynonymous
MTHFD1 methylenetetrahydrofolate dehydrogenase 1 J04031 rs2236225 Nonsynonymous
SHMT1 serine hydroxyl-methyltranferase 1 NM_004169 rs1979277 Nonsynonymous
MTHFR 5,10 methylene-tetrahydrofolate reductase NM_005957 rs1801133 Nonsynonymous
rs1801131 Nonsynonymous
MTR 5-methyltetrahydrofolate-homocysteine NM_000254 rs10925235 Intronic
methyltransferase rs12060570 Intronic
rs10925250 Intronic
rs1805087 Nonsynonymous
rs4659743 intronic
MTRR 5-methyltetrahydrofolate-homocysteine AF025794 rs1801394 Nonsynonymous
methyltransferase reductase
BHMT betaine-homocysteine methyltransferase BC012616 rs651852 Intronic
rs7700970 Intronic
rs3733890 Nonsynonymous
rs558133 Intronic
CBS cystathionine-beta-synthase NM_000071 rs234783 Intergenic
rs234715 Intronic
rs2851391 Intronic
844ins68 —a
rs1789953 Intronic
rs4920037 Intronic
rs1801181 Synonymous
rs9325622 Intronic
rs12613 Intronic
rs412810 Intergenic
Gene annotations are from GenBank (http://www.ncbi.nih.gov/GenBank).
a844ins68 is a 68-bp insertion in exon 8 of CBS.
Figure 2. Genomic location of genotyped SNPs in relation to the three genes with three or more genotyped
SNPs: MTR, BHMT, and CBS.
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Table 3. Single-gene p-values from significant
association tests with an environmental stratum. 
Gene SNP Narrow Broad
symbol data set PDT APL PDT APL
BHMT rs3733890
Full data set 0.023* 0.058 0.025* 0.035*
No suppl. 0.357 0.635 0.245 0.390
Yes suppl. 0.027* 0.055 0.016* 0.027*
BHMT rs558133
Full data set 0.114 0.124 0.026* 0.061
No suppl. 0.765 0.983 0.296 0.657
Yes suppl. 0.036* 0.139 0.012* 0.097
MTHFR rs1801133
Full data set 0.203 0.112 0.317 0.263
No suppl. 0.153 0.046* 0.235 0.102
Yes suppl. 0.529 0.910 0.906 0.657
MTR rs10925235
Full data set 0.877 0.794 0.715 0.865
No suppl. 0.066 0.031* 0.040* 0.027*
Yes suppl. 0.456 0.444 0.789 0.686
MTR rs4659743
Full data set 0.885 0.426 0.547 0.375
No suppl. 0.104 0.013* 0.041* 0.010*
Yes suppl. 0.891 0.972 0.553 0.741
CBS  rs234715
Full data set 0.287 0.617 0.160 0.328
No suppl. 0.056 0.190 0.015* 0.064
Yes suppl. 0.527 0.562 0.435 0.683
CBS  rs4920037
Full data set 0.514 0.787 0.277 0.525
No suppl. 0.122 0.213 0.037* 0.085
Yes suppl. 0.423 0.509 0.435 0.650
Suppl., supplementation with folic acid before conception.
*p < 0.05.Despite being 96.6 kb apart, high LD (D´=
0.973, r2 = 0.946) throughout MTR could
account for both SNPs’ associations (Table 4).
Stratifying by other genes. In complex con-
ditions like NTDs, multiple genes are likely
contributing to folate-related risk. To evaluate
multigenic effects, families were grouped by
preferential transmission of an allele to
affected offspring and reevaluated for all other
SNPs. For BHMT rs373389, 79 families pref-
erentially transmitted the G allele, 59 trans-
mitted the A allele, 149 transmitted both
equally or had homozygous parents, whereas
17 could not be determined and were not
included in the analysis (Table 5). When
the G allele was preferentially transmitted,
the CBS insertion was significant by PDT
(p = 0.033 for both diagnostic groups),
whereas two SNPs were significant by APL:
SHMT rs1979277 (p = 0.042 narrow, p =
0.020 broad) and MTR rs4659743 (p = 0.049
narrow, p = 0.015 broad). When segregating
the A allele, MTHFD1 rs2236225 was signiﬁ-
cant by PDT in the broad phenotypic group
(p = 0.016). Other SNPs in BHMT were
signiﬁcant in the stratiﬁed groups due to inter-
marker LD (Table 4).
We performed a similar analysis stratifying
by transmission of the MTHFR rs1801133
thermolabile T allele (Table 6). Sixty-eight
families were grouped for the T allele; 90 fami-
lies were grouped for the C allele; 134 families
did not preferentially transmit either allele; and
12 were excluded. With overtransmission of
the T allele, BHMT rs3733890 is more signiﬁ-
cant than in any prior analysis (narrow PDT
p = 0.007, narrow APL p = 0.027, broad PDT
p = 0.010, broad APL p = 0.047), and TCN2
rs1801198 was associated by PDT with the
broad phenotype (p = 0.045). For the C allele
subset, rs1801394 in MTRR was signiﬁcant by
APL in the broad group (p = 0.048). When
neither allele was preferred, the SHMT SNP is
significant by PDT (p = 0.050 for narrow,
0.037 for broad).
Discussion
BHMT contributes to the risk of NTDs.
BHMT is signiﬁcantly associated with NTDs in
our sample set, particularly when mothers were
receiving preconceptional folate or parents pref-
erentially transmitted the MTHFR rs1801133
T allele. It is not immediately apparent how
BHMT would increase NTD risk in a folate-
rich environment. In adults, BHMT functions
predominantly in the liver, whereas MTR is
active in all tissues (Zhu et al. 2005), but the
expression patterns in the developing embryo
are unknown and may be markedly different
than that in the adult. BHMT is responsible for
up to 50% of methylation in the adult liver
(Finkelstein and Martin 1984).
The methyl cycle supplies 1-carbon units
critical for a variety of methylation reactions
essential for proper gene expression and mater-
nal and paternal imprinting by methylated
DNA (Razin and Kantor 2005). Growth factor
genes are commonly imprinted in this manner,
and nutrition can alter these methylation pat-
terns (Waterland and Jirtle 2003). Faulty
embryonic methylation of DNA due to abnor-
mal folate levels or improper methyl cycle gene
expression at a critical developmental juncture
could inappropriately silence growth factors
necessary for proper tube closure.
Homocysteine levels are also maintained
by the methyl cycle and play a role in NTD
risk. Large-dose oral betaine therapy, a
BHMT cofactor, treats hyperhomocysteine-
mia by shunting homocysteine through a
betaine-dependent remethylation pathway
(Kang 1996). When folate dependent methio-
nine synthesis is impaired, by either genetic or
environmental factors, BHMT plays a critical
role in homocysteine homeostasis (Weisberg
et al. 2003). However, the BHMT R (G allele)
and Q (A allele) proteins show no differences
in thermostability or enzymatic Michaelis con-
stant (Q = 2.7 and R = 2.8) (Weisberg et al.
2003). The association of hyperhomocysteine-
mia with NTD risk implicates enzymes  such
as MTR, BHMT, and CBS that degrade
homocysteine.
Our observed relationship between
BHMT, folate supplementation, and NTD
risk appears counterintuitive. It is possible that
the stratification method inadvertently
grouped families by an unidentified cofactor
Boyles et al.
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Table 5. Single-gene p-values from significant
association tests when stratified by preferential
transmission of BHMT rs3733890 alleles. 
Gene SNP Narrow Broad
symbol data set PDT APL PDT APL
SHMT1 rs1979277
G allele 0.157 0.042* 0.066 0.020*
A allele 0.096 0.204 0.101 0.247
Neither 0.448 0.522 0.463 0.699
MTR rs4659743
G allele 0.185 0.049* 0.052 0.015*
A allele 0.691 0.184 0.701 0.193
Neither 0.134 0.146 0.169 0.104
CBS 844ins68
G allele 0.033* 0.222 0.033* 0.217
A allele 0.248 0.287 0.285 0.473
Neither 0.842 0.318 1.000 0.560
MTHFD1 rs2236225
G allele 0.701 0.407 0.392 0.225
A allele 0.064 0.214 0.016* 0.093
Neither 0.822 0.666 0.915 0.739
*p < 0.05.
Table 6. Single-gene p-values from significant
association tests when stratified by preferential
transmission of MTHFR rs1801133 alleles. 
Gene SNP Narrow Broad
symbol data set PDT APL PDT APL
BHMT rs3733890
C allele 0.647 0.815 0.405 0.991
T allele 0.007* 0.027* 0.010* 0.047*
Neither 0.335 0.171 0.463 0.143
TCN2 rs1801198
C allele 1.000 0.661 0.814 0.507
T allele 0.056 0.092 0.045* 0.073
Neither 0.829 0.959 1.000 0.932
MTRR rs1801394
C allele 0.109 0.050 0.099 0.048*
T allele 0.439 0.465 0.904 0.805
Neither 0.473 0.601 0.502 0.717
SHMT1 rs1979277
C allele 0.317 0.370 0.279 0.318
T allele 0.475 0.547 0.249 0.295
Neither 0.050* 0.193 0.037* 0.190
*p < 0.05.
Table 4. Linkage disequilibrium (D´ and r2) between SNPs in genes where more than three SNPs were
genotyped in affected individuals.
MTR rs10925235 rs12060570 rs10925250 rs1805087 rs4659743
rs10925235 0.966* 0.9 0.953* 0.973*
rs12060570 0.379 0.962* 0.961* 0.949*
rs10925250 0.122 0.176 1* 0.91*
rs1805087 0.131 0.169 0.976* 0.958*
rs4659743 0.946* 0.36 0.127 0.137
BHMT rs651852 rs7700970 rs3733890 rs558133
rs651852 0.884 0.632 0.226
rs7700970 0.316 0.367 0.334
rs3733890 0.14 0.124 1*
rs558133 0.028 0.02 0.162
CBS rs234783 rs234715 rs2851391 844ins68 rs1789953 rs4920037 rs1801181 rs9325622 rs12613 rs412810
rs234783 0.708 0.786 0.019 0.868 0.69 0.86 0.841 0.111 0.524
rs234715 0.192 0.963* 1* 1* 1* 1* 1* 1* 0.791
rs2851391 0.579 0.383 1* 0.915* 0.964* 0.985* 0.986* 1* 0.781
844ins68 0 0.028 0.068 1* 1* 0.897 0.789 0.971* 0.727
rs1789953 0.13 0.048 0.152 0.012 1* 1* 1* 0.999* 0.694
rs4920037 0.183 0.98* 0.395 0.028 0.049 1* 1* 1* 0.802
rs1801181 0.413 0.21 0.487 0.045 0.096 0.213 0.975* 1* 0.79
rs9325622 0.392 0.214 0.494 0.037 0.094 0.214 0.934* 0.883 0.803
rs12613 0.001 0.026 0.064 0.846 0.012 0.026 0.055 0.043 0.681
rs412810 0.149 0.441 0.372 0.02 0.032 0.456 0.185 0.201 0.017
D’ values are given above the diagonal; r 2 values are given below the diagonal. 
*Linkage disequilibrium > 0.9.Folate genes associated with NTDs
Environmental Health Perspectives • VOLUME 114 | NUMBER 10 | October 2006 1551
correlated with supplementation. The BHMT
polymorphism could also create a highly efﬁ-
cient variant that causes the metabolic cycles
to overfunction when combined with high
folate levels. Human NTDs can only be stud-
ied at birth, not at the true point of incidence
28 days postconception, so we may fail to
observe a high-risk group incompatible with
life. Such individuals with insufﬁcient BHMT
and low folate may not be observable unless
they also have an additional unknown protec-
tive factor. All these hypotheses are highly
speculative, particularly in the absence of any
biological support.
In the subset of families also transmitting
the MTHFR T allele, affected children who
have inherited at least one copy of the thermo-
labile allele from a heterozygous parent are
even more likely to have also received the
BHMT A allele. A gene–gene interaction
between MTHFR and BHMT would require
polymorphisms in both genes for the disorder,
or additional correlated factors are involved
and undetectable in this sample. These results
implicate BHMT in NTD risk alone, in con-
junction with maternal folate supplementation,
and/or a polymorphism in MTHFR that
proper folate metabolism.
Other folate pathway genes implicated.
The most widely studied gene in NTD
research, MTHFR, is not a signiﬁcant risk fac-
tor in our overall data set. In families that did
not receive folate supplementation, the
rs1801133 polymorphism was moderately sig-
niﬁcant. Signiﬁcant prior research combined
MTHFR with other genes, and our results
found BHMT to be highly significant in the
T allele subgroup.
MTHFR rs1801133 is not the only genetic
NTD risk factor, particularly in Caucasian
Americans. Some NTD cases are not folic acid
preventable, and at most 25% of cases can be
solely explained by rs1801133 (Posey et al.
1996; van der Put et al. 1996). Excluding
TT genotype people, there is still a decrease in
folate and increase in homocysteine levels in
patients and their parents (van der Put et al.
1997).
Some previously investigated NTD-related
genes included in this study are less likely to
be involved because of their biochemical func-
tion. For example, FOLR2 is not the primary
binder of folate, therefore the lack of signiﬁ-
cant association does not contradict models of
folate metabolism (Trembath et al. 1999).
Mathematical models of the folate and
methionine cycles indicate that these systems
are quite robust to dietary folate intake and
perform well without signiﬁcant folate intake
for several months (Nijhout et al. 2004).
Conversely, lack of significance does not
rule out their involvement in the etiology of
NTDs. Under a dominant model with a base-
line risk of 0.0001 and a genetic relative risk of
0.6, 300 case–parent trios have a power of 0.62
to detect a main genetic effect at a 0.05 signiﬁ-
cance level. Some genes in our study may be
involved in human NTDs but cannot be
detected with our sample size. In addition, typ-
ing one nonsynonymous SNP in a gene cannot
capture the complete genetic diversity. For key
genes more thorough interrogation requires
exonic, intronic, and regulatory SNPs. The
HapMap provides tagging SNPs based on the
LD structure of the genomic region (Altshuler
et al. 2005). Genes such as MTR are particu-
larly problematic because high LD across a
large region will make it very difﬁcult to iden-
tify causative SNPs. Methionine cycle genes,
such as S-adenosylhomocysteine hydrolase
(AHCY; GenBank accession no. NM_000687),
regulate the production of homocysteine and
should also be investigated.
All SNPs were tested for HWE before
analysis, primarily to identify genotyping
errors. Of all the SNPs tested, only MTHFD1
rs2236225 was out of HWE (p = 0.004) only
in affected individuals. Departure from HWE
in this study could result from genotyping
error, selection, small sample size, or nonran-
dom mating. Unaffected individuals were in
HWE for this SNP, potentially indicating an
association, but no subsequent association was
detected for this SNP. No other SNPs deviated
from HWE, so there does not appear to be a
widespread problem with the ascertainment of
this sample set. Although this HWE deviation
is interesting, it does not affect the overall out-
come of the study because MTHFD1 was not
an implicated gene.
NTDs are a complex disorder involving
many genetic and environmental factors.
Future studies aimed at identifying these risk
factors must approach the problem with a
wide perspective including several genes and
collecting as much environmental data as pos-
sible. Despite substantial efforts to associate
NTDs with folate genes, there is no convinc-
ing evidence of an association for most of
these genes. The role of folate in the etiology
of NTDs could result from epigenetic effects
or interactions with nonfolate genes. All pre-
vious research supports the multifactorial
nature of NTDs underlining the necessity of
multiple approaches in order to disentangle
the contributors to this complex disorder.
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